Document Detail

Understanding the mechanisms and treatment options in cancer cachexia.
MedLine Citation:
PMID:  23207794     Owner:  NLM     Status:  Publisher    
Cancer cachexia is a metabolic syndrome that can be present even in the absence of weight loss ('precachexia'). Cachexia is often compounded by pre-existing muscle loss, and is exacerbated by cancer therapy. Furthermore, cachexia is frequently obscured by obesity, leading to under-diagnosis and excess mortality. Muscle wasting (the signal event in cachexia) is associated not only with reduced quality of life, but also markedly increased toxicity from chemotherapy. Many of the primary events driving cachexia are likely mediated via the central nervous system and include inflammation-related anorexia and hypoanabolism or hypercatabolism. Treatment of cachexia should be initiated early. In addition to active management of secondary causes of anorexia (such as pain and nausea), therapy should target reduced food intake (nutritional support), inflammation-related metabolic change (anti-inflammatory drugs or nutrients) and reduced physical activity (resistance exercise). Advances in the understanding of the molecular biology of the brain, immune system and skeletal muscle have provided novel targets for the treatment of cachexia. The combination of therapies into a standard multimodal package coupled with the development of novel therapeutics promises a new era in supportive oncology whereby quality of life and tolerance to cancer therapy could be improved considerably.
Kenneth Fearon; Jann Arends; Vickie Baracos
Related Documents :
6395824 - The cancer registry in cancer control--a review.
24573604 - The experiences of participants in an innovative online resource designed to increase r...
18759534 - Cancer registry in iran: a brief overview.
8285544 - Closing the audit circle: effect of continuing audit on arthroscopic practice.
8534524 - Using quality of life assessment methods in patients with advanced cancer: a clinical p...
10430404 - Effect of extensive lymph node dissection on the survival of early gastric cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-04
Journal Detail:
Title:  Nature reviews. Clinical oncology     Volume:  -     ISSN:  1759-4782     ISO Abbreviation:  Nat Rev Clin Oncol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500077     Medline TA:  Nat Rev Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Clinical Surgery, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, 51 Little France Crescent, Edinburgh EH16 4SA, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exocyst complex component Sec8: a presumed component in the progression of human oral squamous-cell ...
Next Document:  Potential biomarker for aspirin use in colorectal cancer therapy.